Prospective Registry Of Therapeutic EndoscopiC ulTrasound

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorPaolo Giorgio Arcidiacono, MD

About this trial

This registry aims to analyze long-term outcomes of therapeutic EUS (T-EUS) procedures, as well as to describe clinical and technical variables potentially predicting clinical success or adverse events, for a better selection of ideal candidates.

The study also includes standard alternatives to T-EUS procedures for outcomes comparison.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

subjects candidate to therapeutic EUS (T-EUS) procedures for any underlying disease

subject eligible to T-EUS procedures but undergoing other non-EUS based endoscopic procedures, percutaneous or surgical procedures

18 years old or older

able to provide an informed consent to inclusion.

Disqualifiers

age < 18 years

inability or unwillingness to sign the informed consent form (ICF)

contra-indication for endoscopy or use of fluoroscopy

Trial population

All consecutive patients referred for any condition treatable by therapeutic EUS procedures, benign or malignant, as first intention or after failure of other procedures.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • Therapeutic EUS

    Procedure/Surgery

    1. EUS-guided collection drainage (transgastric or transduodenal, performed by Lumen Apposing Metal Stents or double pigtail stents) and eventual endoscopic necrosectomy 2. EUS-guided biliary drainage (either of the extrahepatic or intrahepatic biliary tree / transduodenal or transgastric / either as access for subsequent rendez-vous or transpapillary stenting OR for transparietal stenting by metal or plastic stents). 3. EUS-guided gallbladder drainage via Lumen Apposing Metal Stents and eventual subsequent EUS-based cholecystolithotomy 4. EUS-guided gastro-jejunostomy through Lumen Apposing Metal Stents 5. EUS-directed ERCP in post-surgical anatomy (by gastro-gastrostomy or entero-enterostomy performed through Lumen Apposing Metal Stents) 6. EUS-guided pancreatic duct drainage

  • Percutaneous Procedures

    Procedure/Surgery

    Procedures involving a percutaneous access to a target region (fluid collection, gallbladder, biliary tree)

  • Surgical Interventions

    Procedure/Surgery

    Surgical interventions to obtain a drainage (e.g. surgical necrosectomy, pancreatico-gastrostomy) or the bypass of a stricture (hepatico-jejunostomy or gastro-jejunostomy)

  • non-EUS-based endoscopic procedures

    Procedure/Surgery

    Other endoscopic procedures not involving EUS (ERCP with stenting; enteral stenting, Enteroscopy-assisted ERCP)

Treatment groups

510 Participants
are divided into 2 treatment groups
Group A: Therapeutic EUS1 intervention
Group B: Controls3 interventions

Trial outcomes

Primary outcomes

1

Clinical Success

* EUS-guided collection drainage: Resolution or reduction of \> 50% of fluid collections * EUS-guided biliary drainage \[valid also for ERCP with stenting\]: Reduction of \>50% of bilirubin OR management of choledocholithiasis OR resolution of cholangitis * EUS-guided gallbladder drainage: Improvement of clinical symptoms or relief of inflammatory signs/symptoms related to cholecystitis * EUS-guided gastro-jejunostomy \[valid also for enteral stenting\]: Resumption of oral intake (Gastric Outlet Obstruction Scoring System \>/= 2 id est at least semisolid food) * EUS-directed ERCP: Possibility to perform ERCP * EUS-guided pancreatic duct drainage: Relief of abdominal pain and reduction of analgesic drug requirement during follow-up OR reduction in the rate of recurrent pancreatitis.

Time frame
30 days

Secondary outcomes

1

Adverse events

Any post-procedural complaint or complication requiring medical consultation or additional procedures, stratified according to American Society of Gastrointestinal Endoscopy Lexicon

Time frame
12 months

Other outcomes

1

Technical success

Completion of the procedure through the correct positioning of the intended device in the target organ

Time frame
1 day
2

Recurrence

A new onset or a worsening of the condition which was palliated through the procedure, after an initial clinical success

Time frame
12 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Paolo Giorgio Arcidiacono, MD

Lead sponsor

IRCCS San Raffaele

Sponsor institution